Gene Silencing Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Gene silencing therapies use nucleic acid-based approaches to reduce or eliminate the expression of disease-causing genes. These therapies target the root cause of genetic neurodegenerative disorders by selectively reducing the production of toxic proteins. The main approaches include antisense oligonucleotides (ASOs), RNA interference (RNAi), and gene editing technologies.
ASOs are single-stranded DNA sequences that bind to complementary messenger RNA (mRNA) through Watson-Crick base pairing. This binding either:
- Promotes RNase H-mediated degradation of the RNA-DNA hybrid
- Modulates splicing to exclude or include specific exons
- Blocks translation initiation or elongation
Key Features:
- Length: 12-25 nucleotides
- Chemistry: 2'-O-methyl, 2'-O-methoxyethyl, phosphorodiamidate morpholino oligomers (PMOs)
- Delivery: Intrathecal for CNS diseases (bypasses BBB)
- Half-life: Several months in CSF
RNAi uses double-stranded RNA molecules to trigger degradation of specific mRNA sequences. The process involves:
- Dicer processing into siRNA or shRNA
- Incorporation into RNA-induced silencing complex (RISC)
- Argonaute-mediated cleavage of complementary mRNA
Key Features:
- More potent than ASOs
- Requires viral or lipid nanoparticle delivery
- Currently in preclinical/early clinical development for CNS
CRISPR-Cas systems enable permanent correction of disease-causing mutations:
- Base editing: Single nucleotide changes without double-strand breaks
- Prime editing: All 12 possible point mutations, insertions, deletions
- Exon skipping: Using ASOs to restore reading frame
- Indication: SOD1-ALS (superoxide dismutase 1 mutations)
- Mechanism: ASO targeting SOD1 mRNA to reduce SOD1 protein production
- Delivery: Intrathecal infusion
- Status: FDA approved (2023)
- Key Trial: VALOR (NCT02623699)
Efficacy:
- Reduced SOD1 protein in CSF (primary endpoint)
- Trended toward slower clinical decline
- Greater effect in patients with faster progression
- Indication: Spinal Muscular Atrophy (SMN1 mutations)
- Mechanism: ASO modifying SMN2 splicing to increase functional SMN protein
- Delivery: Intrathecal
- Status: FDA approved (2016)
- Indication: Hereditary TTR polyneuropathy
- Mechanism: ASO reducing transthyretin (TTR) production
- Delivery: Subcutaneous
- Status: FDA approved (2018)
| Therapy |
Target |
Approach |
Stage |
| BIIB080 |
Tau |
ASO |
Phase 1/2 |
| AAV.Tau |
Tau |
RNAi |
Preclinical |
| BIIB113 |
APOE4 |
ASO |
Phase 1 |
| Therapy |
Target |
Approach |
Stage |
| AAV-GRN |
GBA1 |
Gene therapy |
Phase 1/2 |
| ASO-LRRK2 |
LRRK2 |
ASO |
Preclinical |
| siRNA-alpha-syn |
SNCA |
RNAi |
Preclinical |
| Therapy |
Target |
Approach |
Stage |
| Tominersen |
HTT |
ASO |
Discontinued (Phase 3) |
| VCTX1 |
HTT |
Gene editing |
Phase 1/2 |
| ASO-HTT |
HTT |
ASO |
Phase 1/2 |
| Therapy |
Target |
Approach |
Stage |
| ASO-C9orf72 |
C9orf72 |
ASO |
Phase 1/2 |
| WVE-004 |
C9orf72 |
ASO |
Phase 1/2 |
| ION363 |
FUS |
ASO |
Phase 3 |
- Intrathecal delivery: Direct injection into CSF (most common for ASOs)
- Convection-enhanced delivery: Pressure-driven infusion into brain tissue
- Focused ultrasound: Temporarily opens BBB to enhance delivery
- Nanoparticle carriers: Lipid or polymer-based delivery vehicles
- Viral vectors: AAV for gene-based approaches
- Promoter choice for viral vectors
- Ligand-targeted nanoparticles
- Chemical modification of ASOs
- Injection site reactions (intrathecal)
- Thrombocytopenia
- Hepatotoxicity
- Renal toxicity
- CSF white blood cell elevation
- Unintended silencing of similar sequences
- Immune activation
- Mitochondrial toxicity
- Gene silencing + gene replacement
- Gene silencing + small molecule
- Multiple ASOs targeting different transcripts
- Conjugate ASOs (GalNAc, peptides)
- Brain-penetrant ASOs
- Self-delivering ASOs
- Single administration potential
- Permanent correction
- Can restore physiological expression patterns
The study of Gene Silencing Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Miller TM, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2023;389:109-121. PMID:37163742
- Tabrizi SJ, et al. Targeting Huntingtin in Huntington's Disease. Nat Rev Neurol. 2024;20:145-160. PMID:38148329
- Bennett CF, et al. Antisense Oligonucleotides: Basic Concepts. Nat Rev Drug Discov. 2022;21:548-569. PMID:35680934
- Kordasner MH, et al. RNAi Therapeutics for Neurodegeneration. Nat Rev Drug Discov. 2023;22:743-767. PMID:37414875
- Fellmann C, et al. Cornerstones of CRISPR-Cas9. Nat Rev Mol Cell Biol. 2024;25:67-83. PMID:38096941
- Zeitlin SO, et al. Gene Therapy for Neurodegenerative Diseases. Nat Med. 2024;30:124-134. PMID:38195623